NCT00812812终止4 期
A Randomised, Double-blind, Placebo Controlled, Parallel Group , Flexible Dose Study to Evaluate the Efficacy and Safety of Paxil® Tablets in Children and Adolescents With Major Depressive Disorder<Post-marketing Clinical Study>
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8
研究概览
简要总结
This study is designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily (after evening meal) for 8 weeks in children and adolescents with major depressive disorder (MDD) based on the change from baseline to Week 8/end-of-study in the CDRS-R total score in a randomized, double-blind, placebo-controlled parallel-group study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 7 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •run-in period: A subject will be considered eligible for the study only if all of the following criteria apply at start of placebo run-in period.
- •Patients who are diagnosed with the following depressive disorders according to the DSM-IV-TR criteria, and currently presents with a depressive episodes. Depressive disorders: MDD, single episode (296.2), MDD, recurrent (296.3)
- •7 years and older and under 18 years old (at the time of consent obtained)
- •Patients with a total raw summary score on the CDRS-R of 45 or greater at the Week -2 visit.
- •Patients whose legally acceptable representative (e.g., caretaker, custodian) is able to give written consent to participation to this study. Patients aged 12 and above at the time of consent obtained should be able to sign the informed consent on one's own. Efforts should be exerted in obtaining the informed assent in writing from patients aged less than
- •Patients with ideal body weight +/- 2SD
- •Gender: Male or female
- •treatment period:
- •Subjects who meet the following criteria at Week 0 (Baseline) may be progressed to the Treatment period:
- •Patients with a total raw summary score on the CDRS-R at Week 0 visit of 45 or greater.
- •Exclusion Criteria
- •run-in period:
- •A subject will not be eligible for inclusion to this study if any of the following criteria applies at start of run-in period:
- •Patients who in the investigator's judgment presented with a clinically predominant Axis I disorder other than MDD (e.g. dysthymic disorder, eating disorders, Specific phobia, PTSD, OCD, Panic disorder, etc)
- •Patients with any history of a psychotic episode or psychotic disorder (including schizophrenia ), or complication of these diseases.
- •Patients with a history of a bipolar disorder, or complication of these diseases.
- •Patients with Attention-Deficit, or Hyperactivity Disorder
- •Patients with Mental Retardation or Pervasive Development Disorder
- •Patients diagnosed with Substance Abuse or Dependence within 12 weeks prior to the Screening visit
- •Patients with past treatment experience with the investigational drug (i.e. paroxetine)
- •Patients treated with electroconvulsive therapy in the immediate 12 weeks prior to the Screening visit
- •Patients with past history of serotonin syndrome and neuroleptic malignant syndrome.
- •Patients with CDRS-R score of "suicidal ideation" of 3 or greater. Or patients whose C-SSRS assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the chief investigator (subinvestigator), are at significant risk for harming self.
- •Patients with past history of suicide attempt, self harm(excluding "no suicidal intent " ), or an intentional overdose (excluding obviously unintentional overdose)
- •Patients who have been treated with other clinical trial investigational drug (including post-marketing clinical trial) in the immediate past 3 months of the Week -2 visit.
- •Patients who have taken antidepressant medication 1 week prior to screening.
- •Patients with complicated disease of glaucoma.
- •Patients with convulsive disorders such as epilepsy or past history of these diseases.
- •Patients regularly using drugs (e.g. NSAIDs) that would increase the risk of haemorrhage, or patients with bleeding tendency or haemorrhagic diathesis.
- •Patients with severe renal and hepatic disorder.
- •Patients with serious organic disorder in the brain.
- •Patients with chronic hepatitis type B and/or C which is positive of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody.
- •Patients with a current history of carcinoma or malignant tumor, or complication of these diseases.
- •Female patients who are pregnant, lactating, or who might be pregnant, or who wish to be pregnant during the study period
- •Patients in the opinion of the chief investigator (subinvestigator) judged as not eligible for the study.
- •Patients with clinical significant comorbid impulsivity symptoms.(e.g. Personality Disorder, Conduct Disorder)
- •treatment period: Subjects for whom any of the following categories apply at Week 0 (start of the treatment period) will not be progressed to the treatment phase.
- •Patients with CDRS-R score of "suicidal ideation" of 3 or greater, or patients who, in the opinion of the chief investigator (sub investigator), are at significant risk for harming self
- •Patients with variation of the CDRS-R total raw summary score at Week 0 of +/-25% or greater compared to that of Week -
- •Patients with drug compliance of Drug 1 (run-in placebo) from Week -2 to Week 0 less than 80%.
- •Patients, in the opinion of the chief investigator (sub investigator) judged as not appropriate for the study.
排除标准
- 未提供
研究组 & 干预措施
paroxetine group
Experimental
paroxetine 10-40mg/day
干预措施: matched placebo to paroxetine 10mg (Drug)
paroxetine group
Experimental
paroxetine 10-40mg/day
干预措施: paroxetine 10mg tablet (Drug)
paroxetine group
Experimental
paroxetine 10-40mg/day
干预措施: paroxetine 20mg tablet (Drug)
paroxetine group
Experimental
paroxetine 10-40mg/day
干预措施: matched placebo to paroxetine 20mg (Drug)
placebo group
Placebo Comparator
matched placebo to paroxetine
干预措施: matched placebo to paroxetine 10mg (Drug)
placebo group
Placebo Comparator
matched placebo to paroxetine
干预措施: matched placebo to paroxetine 20mg (Drug)
结局指标
主要结局
Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8
时间窗: Baseline and Week 8
The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 questions. Each question is graded on a 5- or 7-point scale. The highest possible score is 113 (the most severe measure of depression), and the lowest is 17 (not suffering from depression). CDRS-R scores were assessed by the investigator. The change from Baseline in the CDRS-R total score was calculated as the total score at Week 8 minus the total score at Baseline. The data were adjusted with the total score at Baseline.
次要结局
- Plasma Paroxetine Concentrations at 12 Hours and 24 Hours After Administration of Study Drug at Week 8 or Withdrawal(Week 8 or Withdrawal (up to Week 8))
- Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8(Weeks 1, 2, 3, 4, 6, and 8)
- Change From Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6(Baseline and Weeks 1, 2, 3, 4, and 6)
- Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-SI) Score at Weeks 1, 2, 3, 4, 6, and 8(Baseline and Weeks 1, 2, 3, 4, 6, and 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedemaHereditary angioedema (HAE) type I or type II.Haematological DisordersHereditary Angioedema Type I or IIISRCTN14762022KalVista Pharmaceuticals Ltd136
已完成
不适用
A randomized, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate.Rheumatoid arthritis (RA)NL-OMON27198Millennium Pharmaceuticals Inc.186
已完成
不适用
A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumoniaISRCTN13593711Genentech452
进行中（未招募）
不适用
Safety and Efficacy Study of DGLA Cream in Patients with Atopic DermatitisAtopic DermatitisEUCTR2012-003739-44-FIDignity Sciences Limited200
进行中（未招募）
1 期
Safety and Efficacy Study of DGLA Cream in Patients with Atopic DermatitisAtopic DermatitisEUCTR2012-003739-44-DKDignity Sciences Limited200